Pain relief devoid of opioid side effects following central action of a silylated T neurotensin analog
Pascal Tétreault, Élie Besserer-Offroy, Rebecca L Brouillette, Adeline René, Alexandre Murza, Roberto Fanelli, Karyn Kirby, Alexandre J Parent, Isabelle Dubuc, Nicolas Beaudet, et al.

To cite this version:
Pascal Tétreault, Élie Besserer-Offroy, Rebecca L Brouillette, Adeline René, Alexandre Murza, et al.. Pain relief devoid of opioid side effects following central action of a silylated T neurotensin analog. European Journal of Pharmacology, Elsevier, 2020, 10.1016/j.ejphar.2020.173174. hal-03022448

HAL Id: hal-03022448
https://hal.archives-ouvertes.fr/hal-03022448
Submitted on 24 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog

Pascal Tétreault\textsuperscript{a,b,c,d,1}, Élie Besserer-Offroy\textsuperscript{a,c,d,1,2}, Rebecca L Brouillette\textsuperscript{a,c,d}, Adeline René\textsuperscript{e}, Alexandre Murza\textsuperscript{a,c,d}, Roberto Fanelli\textsuperscript{e}, Karyn Kirby\textsuperscript{a,c,d}, Alexandre J Parent\textsuperscript{a,c,d}, Isabelle Dubuc\textsuperscript{f}, Nicolas Beaudet\textsuperscript{b}, Jérôme Côté\textsuperscript{a,c,d}, Jean-Michel Longpré\textsuperscript{a,c,d}, Jean Martinez\textsuperscript{e}, Florine Cavelier\textsuperscript{e,3,*}, Philippe Sarret\textsuperscript{a,b,c,d,3,*}

\textsuperscript{a} Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001 12\textsuperscript{th} Avenue North, Sherbrooke, Québec, J1H5N4, Canada.
\textsuperscript{b} Department of Anesthesiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, 3001 12\textsuperscript{th} Avenue North, Sherbrooke, Québec, J1H5N4, Canada.
\textsuperscript{c} Institut de pharmacologie de Sherbrooke, Université de Sherbrooke, 3001 12\textsuperscript{th} Avenue North, Sherbrooke, Québec, J1H 5N4, Canada.
\textsuperscript{d} Centre de recherche du Centre hospitalier universitaire de Sherbrooke, CIUSSS de l’Estrie – CHUS, 3001 12\textsuperscript{th} Avenue North, Sherbrooke, Québec, J1H5N4, Canada.
\textsuperscript{e} Institut des Biomolécules Max Mousseron, UMR-5247, CNRS, Université Montpellier, ENSCM, 19 Place E. Bataillon 34095 Montpellier cedex 5, France.
\textsuperscript{f} Department of Pharmacy, Faculty of Medicine and Pharmacy, Université de Rouen, 1 rue Thomas Becket, 76821 Mont-Saint-Aignan cedex, France.

\textsuperscript{1} These authors contributed equally to this work
\textsuperscript{2} Present address: Department of Pharmacology and Therapeutics, McGill University, Montréal, Québec, Canada.
\textsuperscript{3} Lead Authors
Email addresses of authors:

Pascal.Tetreault@USherbrooke.ca (PT)
Elie.Besserer@McGill.ca (ÉBO)
Rebecca.Brouillette@USherbrooke.ca (RLB)
Adeline.Rene@gmail.com (AR)
Alexandre.Murza@USherbrooke.ca (AM)
robyfanelli@hotmail.it (RF)
Karyn.Kirby@USherbrooke.ca (KK)
Alexandre.Parent2@USherbrooke.ca (AJP)
Isabelle.Dubuc@univ-rouen.fr (ID)
Nicolas.Beaudet@USherbrooke.ca (NB)
Jerome.Cote@USherbrooke.ca (JC)
Jean-Michel.Longpre@USherbrooke.ca (JML)
Jean.Martinez@umontpellier.fr (JM)
Florine.Cavelier@umontpellier.fr (FC)
Philippe.Sarret@USherbrooke.ca (PS)

*Co-Corresponding Authors:

Philippe Sarret, Ph.D.
Dept of Pharmacology-Physiology
Université de Sherbrooke
3001, 12e Avenue Nord
Sherbrooke, QC, Canada, J1H 5N4
Philippe.Sarret@USherbrooke.ca
Phone: +1 (819) 821-8000 ext. 72554

Florine Cavelier, Ph.D.
IBMM, UMR-CNRS-5247
Université de Montpellier
19 Place Eugène Bataillon
34095 Montpellier Cedex 5, France
Florine.Cavelier@umontpellier.fr
Phone: +33 (0) 467 14 37 65
Chemical compounds studied in this article

Neurotensin (PubChem CID 25077406)

PD149163 (PubChem CID 73064239)
Abstract

Neurotensin (NT) exerts naloxone-insensitive antinociceptive action through its binding to both NTS₁ and NTS₂ receptors and NT analogs provide stronger pain relief than morphine on a molecular basis. Here, we examined the analgesic/adverse effect profile of a new NT(8-13) derivative denoted JMV2009, in which the Pro¹⁰ residue was substituted by a silicon-containing unnatural amino acid silaproline. We first report the synthesis and in vitro characterization (receptor-binding affinity, functional activity and stability) of JMV2009. We next examined its analgesic activity in a battery of acute, tonic and chronic pain models. We finally evaluated its ability to induce adverse effects associated with chronic opioid use, such as constipation and analgesic tolerance or related to NTS₁ activation, like hypothermia. In in vitro assays, JMV2009 exhibited high binding affinity for both NTS₁ and NTS₂, improved proteolytic resistance as well as agonistic activities similar to NT, inducing sustained activation of p42/p44 MAPK and receptor internalization. Intrathecal injection of JMV2009 produced dose-dependent antinociceptive responses in the tail-flick test and almost completely abolished the nociceptive-related behaviors induced by chemical somatic and visceral noxious stimuli. Likewise, increasing doses of JMV2009 significantly reduced tactile allodynia and weight bearing deficits in nerve-injured rats. Importantly, repeated agonist treatment did not result in the development of analgesic tolerance. Furthermore, JMV2009 did not cause constipation and was ineffective in inducing hypothermia. These findings suggest that NT drugs can act as an effective opioid-free medication for the management of pain or can serve as adjuvant analgesics to reduce the opioid adverse effects.

Keywords: unnatural aminoacid, antinociception, constipation, tolerance, formalin, neuropathic.
1. Introduction

Today, opioids remain at the forefront of the pharmacological treatment of chronic pain (de Leon-Casasola, 2013; Gomes et al., 2014). However, opioid therapy is associated with a wide range of side effects, such as constipation, nausea, drowsiness, dizziness, sleep disturbance, dry mouth, respiratory depression and tolerance that negatively affects patients’ well-being and even discourages them for continuing their medications (Benyamin et al., 2008; Bruneau et al., 2018; Devulder et al., 2005; McNicol et al., 2003). In the ongoing opioid crisis, involving drug misuse, abuse, overdose and death (Coyle et al., 2018), there is therefore an urgent need for new, effective and safe non-opioid analgesics to improve the care of patients suffering from chronic pain (Besserer-Offroy and Sarret, 2019).

Among the alternative to opioids, neurotensin (NT) receptors recently emerged as attractive targets to develop new painkillers (Perez de Vega et al., 2018). Through its binding with two G protein-coupled receptors (GPCRs), referred to as NTS$_1$ and NTS$_2$, the tridecapeptide NT(1-13) was indeed found to induce a potent opioid-independent analgesia in a variety of pain paradigms following systemic or central administration (Dobner, 2006; Feng et al., 2014; Kleczkowska and Lipkowsk, 2013; Sarret and Cavelier, 2018). Accordingly, it was pharmacologically demonstrated that the antinociceptive responses induced by NT and its analogs, designed and synthesized based on the minimal biologically active C-terminal region (Arg$^8$-Arg$^9$-Pro$^{10}$-Tyr$^{11}$-Ile$^{12}$-Leu$^{13}$), could not be reversed by the opioid antagonists, naloxone and naltrexone (Behbehani and Pert, 1984; Bredeloux et al., 2006; Osbahr et al., 1981; Wustrow et al., 1995). Importantly, NT was also reported to provide stronger pain relief than morphine on a molecular basis (al-Rodhan et al., 1991; Nemeroff et al., 1979).
In the last two decades, peptide therapeutics have gained increased interest from the biomedical and pharmaceutical industry, filling the gap between the two main classes of available market drugs, small molecules and biologics (Fosgerau and Hoffmann, 2015; Kaspar and Reichert, 2013). Peptides are definitely attractive drug candidates due to their high potency/efficacy, target specificity and safety/tolerability profile. Despite offering many advantages, their extensive use as therapeutics is, however, limited by their short half-life and rapid plasma clearance, which leads to low bioavailability (Fosgerau and Hoffmann, 2015; McGonigle, 2012). Several strategies have therefore been developed to overcome the undesirable physicochemical properties of therapeutic peptides. These approaches successfully applied to the C-terminal NT(8-13) hexapeptide include backbone and side-chain modifications, such as D-amino acid and non-natural amino acid substitutions, incorporation of reduced bonds, lactam bridged mimetics or peptide-peptoid hybrids, N- and C-terminal modifications as well as introduction of conformational constraints via cyclization (Bittermann et al., 2004; Boules et al., 2010; Bredeloux et al., 2008; Einsiedel et al., 2011; Fanelli et al., 2015; Hughes et al., 2010; Labbé-Jullié et al., 1994; Sarret and Cavelier, 2018; Sousbie et al., 2018; Tyler-McMahon et al., 2000; Wustrow et al., 1995).

According to recent structure-activity relationship (SAR) studies, structural modifications with unnatural amino acids were effective in producing NT(8-13) analogs with improved metabolic stability, receptor selectivity and in vivo activity (Boules et al., 2010; Fanelli et al., 2015; Hapău et al., 2016; Hughes et al., 2010; Magafa et al., 2019; Tokumura et al., 1990; Tyler-McMahon et al., 2000). In that respect, non-natural silylated amino acids are of great interest for their ability to modulate the physicochemical properties of bioactive peptides (Cavelier et al., 2004; Cavelier et al., 2002; Dalkas et al., 2010; Fanelli et al., 2017; Fanelli et al., 2015; Remond et al., 2016). Herein, we report the synthesis and in vitro/in vivo characterization of a new NT(8-
13) analog, named JMV2009, which binds to both NTS$_1$ and NTS$_2$ receptors. In this compound, the Pro$^{10}$ residue was substituted by a silicon-containing unnatural amino acid proline surrogate, denoted silaproline (Sip), which has been shown to retain peptide conformation (Cavelier et al., 2006; Cavelier et al., 2002; Remond et al., 2017; Vivet et al., 2000). This Sip-containing NT(8-13) analog was further screened in a battery of pain models to assess its putative analgesic properties and evaluate for its ability to induce adverse effects associated with chronic opioid therapy, such as constipation or analgesic tolerance.
2. Materials and methods

2.1. Materials

PD149163 was obtained by the U.S. National Institute of Mental Health, Chemical Synthesis and Drug Supply Program. Morphine sulfate was purchased from Sandoz (Boucherville, QC, Canada).

2.2. Synthesis and in vitro characterization of JMV2009

Synthesis, chemical characterization, and in vitro and in cellulo characterization (binding, signaling and plasma stability) of JMV2009 are reported into the accompanying Data in Brief article (Besserer-Offroy et al., 2020)

2.3. Animals

Experimental procedures were approved by the Animal Care and Ethical Committee of the Université de Sherbrooke, for experiments involving rats (animal use protocol number 035-18) and were in accordance with policies and directives of the Canadian Council on Animal Care. Experiments involving mice were approved by the Animal Care and Ethical Committee of the Université de Rouen (Cenomax, Agreement of the French Ministry of Research number 54) and were in accordance with policies and directives of the French Council on Animal Care and European Community Council Directive of 24 November 1986 (86:609: EEC). Furthermore, all procedures involving animals followed the ARRIVE recommendations (Kilkenny et al., 2010).

Adult male Sprague-Dawley rats (200-225 g; Charles River Laboratories, St-Constant, Quebec, Canada) or adult male Swiss albino mice (CD1, 22-26 g, Charles River, St-Aubin-les-Elbeuf, France) were both maintained on a 12:12 hrs light/dark cycle with access to food and water ad libitum. Animals were acclimated for four days to the animal facility and for two days to the manipulations and testing devices prior to behavioral studies. The total number of animals
used in this study is 30 mice and 172 rats. Animals were independently and randomly assigned to a saline or treatment group prior any behavioral testing.

2.4. Behavioral studies involving mice

2.4.1. Intracerebroventricular injections

The intracerebroventricular injections (i.c.v.) were performed in conscious mice according to the method of (Haley and McCormick, 1957) in a volume of 10 µl/mouse.

2.4.2. Visceral pain test

The intraperitoneal (i.p.) injection of a chemical irritant in mice induces a visceral noxious response characterized by a wave of constriction followed by elongation of the abdominal wall (Collier et al., 1968). This tonic visceral nociceptive response is often described as the writhing test (Koster et al., 1959). Briefly, mice received an intracerebroventricular (i.c.v.) injection of saline or JMV2009 20 min before i.p. administration of an acetic acid solution (0.5%). The number of writhes produced for a 5-min period was then counted beginning 5 min after i.p. injection.

2.5. Behavioral studies involving rats

2.5.1. Intrathecal injections

Rats were lightly anesthetized with 2% isoflurane. Subsequently, a 25 µl volume of compound or vehicle was administered by injection into the subarachnoid space between lumbar vertebrae L5 and L6, using a 27 G 1/2 needle.

2.5.2. Acute pain test (Tail-Flick test)

Acute nociception was investigated using the tail-flick test. Thermal threshold latencies were determined at baseline and at 10, 20, 30, 40, 50, 60, and 90 min after intrathecal (i.t.) injection of JMV2009 or vehicle. Testing involved measuring the tail withdrawal latency (in s) after immersion in a 52°C water bath. Six centimeters of the rat’s tail were submerged in water
and the latency to flick or curl the tail was recorded. Baseline responses (before drug administration) were typically ranging from 3 to 4 s. A cut-off was imposed at 10 s to avoid tissue damage.

The mean latency at peak effect (40 min) was used for the determination of the analgesic efficacy and was converted to % of maximal possible effect (MPE) according to the formula: 

\[
\% \text{ maximum possible effect} = \frac{\text{test latency} - \text{baseline latency}}{\text{cut-off} - \text{baseline latency}} \times 100.
\]

2.5.3. Formalin tonic pain test

Persistent pain was assessed using the formalin test. For this purpose, rats were placed for a 60-min habituation period in the experimentation room two days before the test. On the test day, rats received 50 μl subcutaneous injection of diluted 2% formaldehyde into the plantar surface of the right hind paw five min. after i.t. injection of JMV2009 or saline. Rats were then immediately placed in clear plastic chambers (40 × 30 × 30 cm) positioned over a mirror angled at 45°, to allow an unobstructed view of the 4 paws. Behaviors were recorded for the next 60 min.

An intra-plantar injection of formalin produces a biphasic nociceptive response that characterizes this tonic pain model (Sawynok and Liu, 2004). The two distinct phases of spontaneous pain behaviors that occur in rats are suggested to reflect a direct effect of formalin on sensory receptors (phase 1) and a longer lasting pain due to inflammation and central sensitization (phase 2). The nocifensive behaviors were assessed using a weighed score, as described previously by (Dubuisson and Dennis, 1977). A nociceptive mean score was determined for each 3-min period by measuring the amount of time spent in each of four behavioral categories: 0, the injected paw is comparable to the contralateral paw; 1, the injected paw has little or no weight placed on it; 2, the injected paw is elevated and is not in contact with
any surface; 3, the injected paw is licked, bitten, or shaken. The total AUC for the inflammatory phase (phase 2) was calculated between 21 to 60 min for each animal (Gaumond et al., 2007).

2.5.4. Chronic Construction Injury (CCI) of the sciatic nerve

2.5.4.1. Surgical procedure

The surgical procedure of the neuropathic pain model was performed as previously described by (Bennett and Xie, 1988) with a modification in the suture used (5-0 Prolene, Ethicon, Inc. Somerville, NJ, USA) in order to minimize suture-induced inflammation. Briefly, animals were anesthetized using 3% isoflurane and the left sciatic nerve was loosely ligatured with 4 sutures distant by 1 mm upstream of the tibial, sural, and common peroneal nerve trifurcation. The muscle, conjunctive tissue and skin were closed with proper sutures and washed with 3% (v/v) hydrogen peroxide. Sham animals received the surgery, but no ligation of the sciatic nerve was performed. Rats were housed for 24 h in separate cages to recover from the surgery and were not given any medication to control post-surgical pain.

The pain-related behaviors were examined at day 0 (pre-surgery, considered the baseline [BL]) and at 3, 7, 14, 21, and 28 days after nerve injury. Animals were moved to the examination room at 8 a.m. and tested one h later. Dynamic weight bearing (DWB) measurements were conducted immediately after the mechanical allodynia assessment.

2.5.4.2. Evaluation of mechanical allodynia

To determine the presence of mechanical allodynia, rats were placed in enclosures with an elevated wire mesh floor. A dynamic plantar aesthesiometer (Ugo Basile, Stoelting, IL, USA), consisting of a metal probe (0.5 mm diameter), was directed against the hind paw pad exerting an upward force (3.33 g/s). The force required to elicit a withdrawal response was measured in grams and automatically registered when the paw was withdrawn, or the pre-set cut-off was reached (50 g). Five values were taken alternately on ipsi- and contra-lateral hind paw at 15 s
intervals. The percentage of anti-allodynia was calculated with the AUC of every treatment for the time period comprised between 3 and 28 days, with the use of the following equation: \(\%\) anti-allodynia = \(100 \times \frac{[(CCI + drug) - CCI\ control]}{(sham - CCI\ control)}\). From the latter formula, 0\% represents no anti-alldynic effect of the compound, while 100\% corresponds to a complete relief of mechanical hypersensitivity.

2.5.4.3. Dynamic weight bearing measurements

The DWB device (Bioseb, Boulogne, France) was used to evaluate the presence of non-evoked pain. This apparatus was characterized previously by our group (Tétreault et al., 2011). Briefly, rats are allowed to move freely within a Plexiglas enclosure (22 × 22 × 30 cm) with a floor sensor composed of 44 × 44 captors (10.89 mm\(^2\) per captor). Pressure data and live recording are recorded and transmitted to a laptop computer. Raw pressure and visual data were colligated with the latest DWB software available at the time. To calculate weight recovery and rehabilitation, we used the same formula as the anti-allodynia, meaning that: % weight recovery (or rehabilitation) = \(100 \times \frac{[AUC(CCI + drug) - AUC(CCI\ control)]}{[(AUC(sham) - AUC(CCI\ control))]}\). From this formula, 0\% represents no weight recovery (or rehabilitation) induced by the compound, while 100\% corresponds to complete weight recovery or total rehabilitation.

2.6. Monitoring of the adverse effects

2.6.1. Gastro-intestinal motility assessment

Constipation has been assessed by measuring the gastro-intestinal (GI) tract motility using the charcoal meal test. Food deprived (16 h) animals were injected s.c. with saline or the compounds to be tested. 30 min. after drug injection, 2-ml of a charcoal meal solution (5\% arabic gum, 10\% charcoal in water) was administered to the rats by gavage. Rats were euthanized exactly 60 min after, and the progression of the charcoal in the intestine was measured as a ratio of progression of the meal over the total length of the intestine. The results are presented as a
percentage of progression of the charcoal meal in the intestine.

2.6.2. *Tolerance to the acute thermal pain test*

For tolerance experiments, rats were injected i.t. with 30 µg/kg/day of JMV2009 or with saline for five consecutive days. On the sixth day, tail-flick latencies were measured immediately before and over 90 min following i.t. injection of JMV2009 (90 µg/kg). The analgesic effect of this sub-chronic treatment was assessed using the tail-flick thermal sensitivity assay as described above.

2.6.3. *Blood pressure monitoring*

Male Sprague-Dawley rats were anesthetized with a mixture of ketamine/xylazine (87 mg/kg:13 mg/kg, i.m.) and placed in supine position on a heating pad. Mean, systolic and diastolic arterial blood pressure as well a heart rate were measured through a catheter (PE 50 filled with heparinized saline) inserted in the right carotid artery and connected to a Micro-Med transducer (model TDX-300, USA) linked to a blood pressure Micro-Med analyzer (model BPA-100c). Another catheter was inserted in the left jugular vein for bolus injections (1 ml/kg, 5-10 s) of vehicle (isotonic saline), NT[8-13] or JMV2009. For relative potency evaluation, changes in mean arterial blood pressure (ΔMABP) from baseline to post-injection in individual animals were determined.

2.6.4. *Core body temperature*

Body temperature was measured using a thermistor probe inserted into the rectum of adult Sprague-Dawley rats. Prior to testing, animals were individually acclimatized to manipulations and thermistor probe 5 min/day for three consecutive days. On the test day, temperature was measured before (baseline) and each 30 min for up to 90 min following i.t. injection of saline, JMV2009 (3, 30 and 90 µg/kg) or the NTS1-selective reference compound PD149163 (Feifel et al., 2010). Variations in body temperature (Δ body temp) were determined as changes from baseline for each individual animal.
2.7. **Data analysis and statistical procedures**

Data were plotted as mean ± standard error (S.E.M.) for all curves and bar graphs. Two-way ANOVAs followed by a Dunnett's post hoc test were performed for all curves. Kruskal-Wallis followed by a Dunn’s correction for multiple comparisons tests were performed for all bar graphs except for the weight recovery and rehabilitation where a Mann-Whitney rank comparison test was used. Prism v7.0a software was used for all statistical analyses. A $P$ value $< 0.05$ was considered significant and significant differences between groups were represented by * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$. Dose-response curve was analyzed by using the log(agonist) vs. response (three parameters) non-linear regression fit of GraphPad Prism v7.0a.
3. Results

3.1. JMV2009 acts as a non-selective NT receptor agonist

We report here the synthesis and pharmacological evaluation of a NT(8-13) analog (JMV2009) carrying an unnatural silicon-containing proline surrogate, the 4-(dimethyl)silaproline (Sip) in replacement of the proline residue at position 10 (Fig. 1-2 and Scheme 1 of the accompanying Data in Brief article). We first found that this silaproline-containing peptide exhibited relatively high and similar binding affinities for both NTS₁ and NTS₂ receptors, with only slightly reduced affinity compared to the native NT peptide (Fig. 3 and Table 1 of the accompanying Data in Brief article). Our results further demonstrated that the presence of this silylated proline residue at position 10 can increase peptide resistance to proteolytic degradation. Accordingly, around 80 % of JMV2009 remained intact after a 5-min incubation with rat plasma, compared to 15 % for the native NT peptide, thus resulting in an improved peptide stability to proteases (Fig. 4 of the accompanying Data in Brief article).

We next examined if this NT peptide derivative was still able to induce receptor activation, by studying its ability to stimulate known intracellular signaling pathways activated by the NT receptor family. We first evaluated the ability of JMV2009 to trigger the activation of different G proteins (Gα₉, Gα₁₃, Gα₁₁, and GαₒA) and the recruitment of β-arrestins 1 and 2 as it was previously reported for NTS₁ endogenous ligands (Besserer-Offroy et al., 2017). We found that JMV2009 was able to activate the four studied G proteins as well as to promote the recruitment of both β-arrestins 1 and 2 (Fig. 5 and Table 2 of the accompanying Data in Brief article). We next evaluated the phosphorylation level of the mitogen-activated protein kinase ERK1/2 after NT or JMV2009 stimulation using cell lines stably expressing either NTS₁ or NTS₂ receptors. Our results revealed that JMV2009 was able to induce ERK1/2 activation in a similar
manner as NT in both NTS$_1$- and NTS$_2$-expressing cells (Fig. 6 of the accompanying Data in Brief article). We then assessed the ability of JMV2009 to trigger NT receptor internalization by cell surface enzyme-linked immunosorbent assay (Fig. 7 and Table 3 of the accompanying Data in Brief article). We observed that both NT and JMV2009 promoted NTS$_1$ receptor internalization, resulting respectively in 59.4 ± 1.5% and 49.1 ± 1.4% reduction in receptor cell surface expression within 1 h. Likewise, NT and JMV2009 induced NTS$_2$-receptor internalization after 60 min of stimulation. Altogether, these results demonstrate that the substitution of Pro$^{10}$ by Sip leads to a functional NT agonist that might be associated with antinociceptive properties.

### 3.2. Central delivery of JMV2009 significantly reduces acute and tonic pain

We first used the tail-flick acute pain model to evaluate whether intrathecal (i.t.) delivery of JMV2009 attenuated the withdrawal responses to thermal nociceptive stimuli. We found that i.t. delivery of JMV2009 in rats elicited a dose-dependent antinociceptive response up to 60 min after injection, characterized by an increased tail-flick latency compared to saline-treated animals (Fig. 1A). Peak analgesic responses occurred 40 min after JMV2009 injection, tail-flick latencies returning to baseline by 90 min. Comparison of % MPE at 40 min following JMV2009 administration showed significant antinociceptive effects for each dose tested. Antinociception reached 35.2 ± 3.2%, 43.4 ± 8.9%, and 62.0 ± 7.7% at doses of 3, 30 and 90 µg/kg, respectively (Fig. 1B).

We then assessed the efficacy of JMV2009 to alleviate the nociceptive behaviors in two different persistent pain paradigms, using either intraplantar formalin or intraperitoneal injection of acetic acid as chemical somatic and visceral noxious stimuli, respectively. Intraplantar injection of formalin into the right hind paw of saline-pretreated rats induced a biphasic time-dependent increase in pain score (Fig. 2). Importantly, i.t. pretreatment with JMV2009
significantly reduced the stereotypical nocifensive behaviors elicited by formalin during the tonic inflammatory phase (21 to 60 min), without affecting the early phase (1 to 9 min) (Fig. 2A). Indeed, both doses tested markedly abolished the spontaneous persistent pain-related behaviors, reaching 49.7 % and 97 % of inhibition at 3 and 30 µg/kg, respectively (Fig. 2B). The antinociceptive effect of JMV2009 was further tested using the acetic acid-induced writhing model in mice (Fig. 2C). We found that i.c.v. injection of JMV2009 suppressed the visceral pain behaviors in a dose-dependent manner, reducing the number of writhes by 87 % at the highest dose tested and displaying a calculated ED$_{50}$ value of 2.33 ± 0.6 µg/kg (Fig. 2D).

### 3.3. JMV2009 attenuates neuropathy-induced mechanical hypersensitivity and improves the quality-of-life proxies

We next investigated the antinociceptive action of JMV2009 in a clinically relevant model of chronic neuropathic pain. Neuropathic pain was induced by chronic constriction injury (CCI) of the sciatic nerve and the mechanical hypersensitivity was determined by applying von frey filaments. As shown in Fig. 3, CCI rats developed tactile allodynia as soon as 3 days after surgery compared with preoperative values and persisted until at least 28 days. As expected, the paw withdrawal thresholds in response to tactile stimuli were not affected in sham-operated animals. Importantly, i.t. injection of JMV2009 was effective in reversing the allodynic state, even at the lowest dose tested (Fig. 3A). Indeed, JMV2009 produced robust anti-allodynic effects, achieving 51.4 ± 3.4 %, 69.2 ± 3.9 % and 66.2 ± 7.6 % of pain relief at the doses of 3, 30 and 90 µg/kg, respectively (Fig. 3B).

To date, the development of potential analgesic agents relies mainly on the measurement of withdrawal responses to acute application of external heat or mechanical stimuli (e.g., von frey filament). However, to improve the translation of analgesics to the clinic, it may be useful to
monitor spontaneous innate behaviors indicative of animal well-being in the preclinical drug screening. Accordingly, we previously demonstrated in different chronic pain models that the dynamic weight bearing (DWB) method could be used to measure posture-locomotor functional impairment and rehabilitation as well as health and quality-of-life outcomes in freely moving rats (Tetreault et al., 2013; Tétreault et al., 2011). In addition to the reflexive mechanical nociceptive test, we thus used the DWB device to assess the effects of JMV2009 on weight load deficits and time-of-use of the injured paw. We first found that i.t. delivery of JMV2009 was effective to reverse the weight bearing deficit induced by the chronic constriction injury of the sciatic nerve (Fig. 4A). Indeed, a 30-µg/kg dose of JMV2009 significantly reduced the ipsilateral paw weight load deficits in non-restrained neuropathic rats, leading to a gain of 40.9 ± 6.4 % of weight recovery over the 28-day period of observation (Fig. 4A-B). Next, we evaluated the efficacy of JMV2009 to reverse the impaired use of the affected limb. As shown in Fig. 4C, JMV2009 improved the time spent by the animal on its injured paw. The drug effectiveness was also expressed as % of rehabilitation within the four-week period, where 100% rehabilitation corresponds to a complete recovery of the paw usage. This outcome parameter is considered clinically relevant and represents a good indicator of quality of life improvement (Cobos et al., 2012). At the dose used, JMV2009 was found to improve the use of the affected limb to 52.8 ± 10.3% (Fig. 4D).

3.4. JMV2009 displays a safer profile compared to opioids or other NT derivatives

To achieve good analgesia, patients’ compliance to a prescribed pain treatment is of high importance. Among the various reasons of noncompliance, the presence of mild to severe side effects seriously affects medication adherence in patients with chronic pain (Benyamin et al., 2008). For instance, constipation, nausea, respiratory depression and tolerance are common clinical concerns that may lead to discontinuation of long-term opioid therapy. Here, we therefore
assessed whether JMV2009 could induce constipation after systemic administration, as it is reported that NT and NT derivatives could have a direct effect on smooth muscles of the intestine in isolated ileum organ bath (Fanelli et al., 2015). To this end, we measured the effects of JMV2009 and morphine on the gastrointestinal tract motility using the charcoal meal test in starved rats (Fig. 5A). Morphine (10 mg kg\(^{-1}\) s.c.) was found to reduce by 45% the progression of the charcoal meal in the intestine, when compared to saline-treated animals. By contrast, both NT and JMV2009 subcutaneously injected at 10 mg kg\(^{-1}\) did not affect the charcoal meal intestinal transit. Rats treated with JMV2009 even showed an almost significant increase of the gastrointestinal tract motility, since the charcoal meal travelled 98.7 ± 0.8 % of the intestine (\(P = 0.064\)) compared to 82.2 ± 2.4 % and 87.4 ± 2.5 % when rats were treated with either NT or saline, respectively (Fig. 5A).

We next determined whether repeated injection of JMV2009 induced the development of tolerance to its analgesic effect. For this purpose, rats were subjected to i.t. injections of JMV2009 (30 µg/kg) daily for five consecutive days, and tail-flick tests were conducted over 90 min on the last day to evaluate changes of JMV2009-induced antinociception. In this experimental paradigm, repeated JMV2009 exposure did not produce tolerance, as demonstrated by the absence of changes in tail-flick latency, when compared to saline pre-treated animals (Fig. 5B). Next, since NT administered centrally also causes hypothermia through an NTS\(_1\)-dependent mechanism (Bissette et al., 1976; Feifel et al., 2010), we measured the ability of JMV2009 to induce changes in body temperature after central administration. We found here that JMV2009 administered i.t. at effective analgesic doses did not induce hypothermia. In sharp contrast, the NTS\(_1\)-selective agonist PD149163, used here as a reference compound induced a pronounced time-dependent drop in body temperature (Fig. 5C). Finally, we investigated the ability of JMV2009 to induce changes in blood pressure after systemic injection. We found here that a dose
of 0.1 mg kg$^{-1}$ of JMV2009 injected i.v. was able to induce a drop of blood pressure similar to the one induced by the same dose of NT. Changes in mean arterial blood pressure (MABP) were found to be of -29.2 ± 5.7 mmHg for rats receiving JMV2009 compared to -25.0 ± 2.5 mmHg for NT-injected animals (Fig. 5D).
4. Discussion

G-protein coupled receptors are the target of more than 25% of the FDA-approved drugs (Overington et al., 2006) and represent one of the largest classes of therapeutic targets in pain medicine (Stone and Molliver, 2009). Nowadays, validation of new molecular targets and development of new effective, non-addicting pain medications are critical, but still remain extremely slow (Kissin, 2010; Yaksh et al., 2018). In the past decades, both NTS1 and NTS2 have generated a growing interest as potential targets for pain treatment (Dobner, 2006; Feng et al., 2014; Kleczkowska and Lipkowski, 2013; Sarret and Cavelier, 2018). This increasing attention is probably driven in part by the fact that NT drugs act as effective opioid-free medications for pain management, producing significant pain relief in various animal models of acute and chronic pain, including neuropathic pain for which opioids have shown their limitations (Guillemette et al., 2012; Perez de Vega et al., 2018; Tetreault et al., 2013). Importantly, the combination of NT analogs to opioids has also the potential to exert complementary (synergistic or additive) analgesic actions, thereby minimizing the adverse effects related to chronic opioid use (Boules et al., 2011; Boules et al., 2009; Eiselt et al., 2019).

In recent years, changes in the pharmaceutical industry have led to renewed interest in the use of peptides as therapeutics (Fosgerau and Hoffmann, 2015; Kaspar and Reichert, 2013). The current pipeline of peptide therapeutics includes over 60 approved drugs and 150 in active clinical development, with 40% of these peptide drug candidates targeting GPCRs (Lau and Dunn, 2018). The development of peptide drugs with high therapeutic potency remains however challenging and requires the implementation of chemical strategies and/or computational structural prediction to synthesize modified peptides with improved stability, pharmacokinetics and in vivo activity profiles. Among the chemical approaches used to optimize the properties of
the NT(8-13) peptide, incorporation of unnatural amino acids, such as N-methylarginine, D-ornithine, D-α-naphthylalanine, tert-leucine or L-(trimethylsilyl)alanine respectively at positions 8, 9, 11, 12 and 13, has been shown to be effective, increasing significantly NTS₁ and NTS₂ receptor binding affinity or selectivity as well as peptide stability and in vivo biological activity (Boules et al., 2010; Fanelli et al., 2015; Hughes et al., 2010; Rossi et al., 2010; Tokumura et al., 1990; Tyler-McMahon et al., 2000). To date, only few studies have investigated the impact of Pro¹⁰ substitutions on NT receptor binding and to our knowledge, none of them have evaluated their efficacy in vivo. The proline residue in position 10 plays a crucial role for peptide conformation and SAR studies reveal that substituted proline analogs that promote a reverse turn are more tolerated than those inducing an extended backbone conformation (Bittermann et al., 2004; Held et al., 2013; Heyl et al., 1994). Indeed, replacement of Pro¹⁰ by thioproline, hydroxyproline, its 4 and 6 member ring counterparts azetidine carboxylic acid and pipecolic acid, or Tic and Aic cyclic aromatic derivatives all induces conformational changes resulting in a significant loss of NT receptor binding affinity (Bittermann et al., 2004; Heyl et al., 1994). These results are consistent with the crystal structure of the NTS₁-NT(8-13) complex in its activated-like conformation, which shows a tight oriented hydrophobic binding site for the pyrrolidine ring of Pro¹⁰ as well as extensive van der Waals interactions with the residue W339 in ECL3 (Krumm et al., 2016; White et al., 2012). Here, we have therefore replaced Pro¹⁰ by a silylated proline surrogate that exhibits very similar conformational properties that the proline residue in peptides (Remond et al., 2016, 2017). The substitution of the γ-carbon by a dimethylsilyl group was found to slightly decrease the affinity of JMV2009 for NTS₁ while this chemical substitution seemed to be adequate for NTS₂ binding. Accordingly, proline isostere bearing a thiazolidine unit instead of the pyrrolidine ring, as well as fluoro-substituted proline analogs on Cγ have already been reported to be well tolerated when incorporated into NTS₂-selective peptoids (Held et al., 2013).
This Sip-containing NT(8-13) peptide also exhibited an improved resistance to proteolytic degradation, probably to the endopeptidases 24.11 and 24.16 responsible for inactivating NT by cleaving at the Pro^{10}-Tyr^{11} bond (Labbé-Jullié et al., 1994; Myers et al., 2009). The steric hindrance of the dimethyl group borne by the silicon atom could indeed induce a misrecognition of the Sip^{10}-Tyr^{11} peptide bond by these metallo-endopeptidases. To further increase the plasma stability of this NT derivative, it would be interesting to combine the substitution of Pro^{10} by Sip to N-terminal protection through the incorporation of blocked amino group (i.e. N_{\alpha}-methylarginine) at position 8 or reduced amide bond between positions 8 and 9 as well as to replace Ile^{12} by a tert-leucine residue to avoid enzymatic cleavage at the Tyr^{11}-Ile^{12} peptide bond (Dubuc et al., 1992; Fanelli et al., 2015; Tokumura et al., 1990). Importantly, this Sip-containing NT(8-13) analog was effective in triggering intracellular signaling responses at both NTS\textsubscript{1} and NTS\textsubscript{2}, as shown by the activation of G proteins, recruitment of β-arrestins, ERK1/2 activation and receptor internalization (Besserer-Offroy et al., 2017; Besserer-Offroy et al., 2020; Gendron et al., 2004).

We then reported the analgesic efficacy of this silylated NT(8-13) analog in different experimental pain models. We first found that JMV2009 was able to significantly reduce acute thermal pain, even at the lower dose of 3 µg/kg. This result is consistent with previous studies demonstrating that both NTS\textsubscript{1} and NTS\textsubscript{2} agonists decrease the tail and foot withdrawal nociceptive responses to noxious heat stimuli (Boules et al., 2009; Hughes et al., 2010; Rossi et al., 2010; Sarret et al., 2005). In persistent pain paradigms, JMV2009 was also able to totally abolish the nociceptive behaviors induced by either intraplantar injection of formalin or visceral noxious stimulation. Interestingly, JMV2009 displays more potent analgesic effects in the formalin pain model than the other non-selective NT analogs, NT69L and JMV2007 previously described (Fanelli et al., 2015; Roussy et al., 2008). At equimolar dose, it is also more potent than
the metabolically stable NTS₂-selective analog JMV431 in reducing the formalin-induced nocifensive behaviors (Roussy et al., 2009). In the peripheral neuropathic pain model, JMV2009 induced relief of CCI-induced evoked hypersensitivity and ongoing pain. Indeed, we first observed that acute i.t. administration of JMV2009 was effective in reversing the development of tactile allodynia in nerve-injured rats. These data thus reinforce previous findings demonstrating that central or systemic delivery of either NTS₁ or NTS₂ agonists reduces the mechanical hypersensitivity in preclinical models of neuropathic pain (Demeule et al., 2014; Guillemette et al., 2012; Hughes et al., 2010; Tetreault et al., 2013). Finally, and perhaps most importantly, the spinal delivery of JMV2009 was also able to reverse significantly the weight bearing deficits as well as to improve the rehabilitation outcomes. In freely moving rats, we indeed found that JMV2009 induced partial recovery of the weight load on the injury leg and increased the time-of-use of the affected limb. The monitoring of these spontaneous nociceptive-related behaviors is now considered critical for evaluating the effectiveness of new drugs (Deuis et al., 2017; Mogil, 2009; Tappe-Theodor and Kuner, 2014). Most behavioral tests currently used rely only on the measurement of stimuli-evoked pain behaviors, such as mechanical hyperalgesia and allodynia. However, neuropathic pain patients predominantly suffer from non-evoked ongoing and spontaneous pain, and not from stimulus-evoked hypersensitivity. This type of pain is the one having the most negative impact, seriously affecting the patient’s daily activities and quality of life, and leading to multiple comorbid conditions, such as mood and anxiety disorders, sleep perturbation, depression or attention deficits. Compared to the previously reported NT(8-13) analog, JMV431, JMV2009 produces stronger anti-allodynic effects in CCI-treated animals as well as substantial improvement in the management of the health and quality-of-life outcomes (Tetreault et al., 2013). Finally, when compared to typical first- and second-line medications for neuropathic pain, JMV2009 appeared as potent as the tricyclic antidepressant amitriptyline and
more effective than morphine, pregabalin, gabapentin and ibuprofen in relieving spontaneous pain behaviors (Angeby-Moller et al., 2008; Deseure and Hans, 2017; Nakazato-Imasato and Kurebayashi, 2009; Tetreault et al., 2013).

Adherence to long-term opioid therapies represents a very clinical issue. Indeed, although opioids, such as morphine have been shown to be effective in relieving pain, the development of bothersome side effects may outweigh the benefits of opioid treatment and even lead to prompt discontinuation of the drug treatment (Benyamin et al., 2008; Besserer-Offroy and Sarret, 2019). Constipation is particularly difficult to manage since patients don’t usually develop tolerance upon repeated morphine administration (Bowers and Crannage, 2017). Likewise, tolerance to the respiratory depressant effects of opioids develops only slowly and incompletely, putting patients at risk for respiratory depression with dose escalation (Algera et al., 2019). Furthermore, the long-term use of opioids can lead to analgesic tolerance and opioid-induced hyperalgesia (Chu et al., 2006). Unlike morphine, we found here that both NT and JMV2009 did not cause constipation. On the contrary, JMV2009 seemed to induce better gastrointestinal transit compared to NT-injected rats. These results are consistent with previous studies demonstrating that NT stimulates colonic motility in rats, cats and humans (Hellstrom and Rosell, 1981; Pellissier et al., 1996; Thor and Rosell, 1986). Supporting a role for NT in propulsive colonic motility is also the finding that i.v. injection of NT in human subjects stimulates defecation and may improve the intestinal movements in colons of patients with slow transit constipation (Calam et al., 1983; Tomita et al., 2007). We further demonstrated that JMV2009 did not produce analgesic tolerance following repeated agonist administration. Accordingly, various NT analogs, such as [D-Trp\textsuperscript{11}]-NT, ABS212 and β-lactotensin do not induce the development of antinociceptive tolerance (Dubuc et al., 1994; Hughes et al., 2010; Yamauchi et al., 2003). We also showed that JMV2009 was ineffective for inducing hypothermia, as opposed to the NT(8-13) agonist PD149163 that
triggered a sustained decrease in body temperature at equimolar dose. This result is quite surprising since most NT agonists acting at NTS$_1$ can produce a significant drop in body temperature (Bissette et al., 1976; Fantegrossi et al., 2005; Feifel et al., 2010). Nevertheless, few NT analogs acting at NTS$_1$ were previously reported to be able to distinguish between hypothermia and analgesia, such as the NT(8-13) analogs, NT27 and NT77L (Boules et al., 2001; Tyler et al., 1998). The concept of ligand biased signaling provides support to the idea that NT analogs acting at NTS$_1$ may have the ability to part between analgesia and hypothermia by recruiting different receptor downstream signaling pathways (Kenakin, 2019). Finally, we showed that JMV2009, when injected systemically, was able to induce a drop in blood pressure which was comparable to the drop induced by NT. This effect, mediated by NTS$_1$, can be triggered after an i.v. injection of a non-selective neurotensinergic compound but also after i.t. delivery at higher doses (Zogovic and Pilowsky, 2012). Indeed, as shown by Zogovic and Pilowsky, administration of at least 75 µM of NT is required to lower blood pressure after spinal delivery (Zogovic and Pilowsky, 2012). For comparison purposes, the analgesic dose of 30 µg/kg of JMV2009 corresponds to an injection of less than 500 nM (for a rat weighting 300 g). Finally, NT- and opioid-related adverse effects could be mitigated by the use of combining neurotensinergic and opioidergic ligands either bi-topic ligands or combination therapy, as recently demonstrated using systemic injections of morphine combined to a brain-penetrant NT agonist (Eiselt et al., 2019; Klczkowski et al., 2010).

5. Conclusion

In conclusion, we demonstrate here for the first time that the NT(8-13) peptide can accommodate the substitution of the proline residue to give rise to a powerful analgesic peptide. We further provide evidence that NT agonists do not induce the common adverse effects
associated with the use of opioids (i.e. constipation and tolerance), thus offering a non-opioid option for the treatment of pain. Finally, these findings suggest that NT agonists used combined with opioid therapy might contribute to adequate pain relief, while reducing the severity of opioid- and neurotensin-driven adverse events.
Authors contributions

Pascal Tétreault: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Writing – Original Draft, Writing – Review & Editing, Visualization.

Élie Besserer-Offroy: Conceptualization, Methodology, Validation, Formal Analysis, Investigation, Writing – Original Draft, Writing – Review & Editing, Visualization.

Rebecca L Brouillette: Investigation.

Adeline René: Ressources.

Alexandre Murza: Investigation.

Roberto Fanelli: Ressources.

Karyn Kirby: Investigation.

Alexandre J Parent: Investigation.

Isabelle Dubuc: Investigation.

Nicolas Beaudet: Conceptualization, Validation, Formal Analysis.

Jérôme Côté: Investigation.

Jean-Michel Longpré: Conceptualization, Validation, Formal Analysis.

Jean Martinez: Ressources, Supervision.

Florine Cavelier: Ressources, Writing – Review & Editing, Supervision, Funding Acquisition.

Philippe Sarret: Conceptualization, Validation, Formal Analysis, Supervision, Funding Acquisition.

All the authors approved the version of the manuscript to be published.

Acknowledgements

PT is the recipient of a post-doctoral fellowship from the Canadian Institutes for Health Research (CIHR, grant MFE-135472). ÉBO is the recipient of a Fond de recherche du Québec – Santé
(FRQ-S, grant 255989) and a CIHR (grant MFE-164740) research fellowships. RLB has been awarded an FRQ-S and a Faculty of Medicine and Health Sciences of the Université de Sherbrooke Ph.D. scholarships. PS is the recipient of a Tier 1 Canada Research Chair in Neurophysiopharmacology of Chronic Pain and a member of the FRQ-S-funded Québec Pain Research Network (QPRN). The National Institute of Mental Health (NIMH) is acknowledged for providing us with the NTS$_1$-selective compound PD149163.

**Funding sources**

This research was supported by grants from the Canadian Institutes for Health Research [grant numbers MOP-74618, FDN-148413]

**Conflicts of interest**

The authors declare that they have no known competing financial interests or personal relationships which have, or could be perceived to have, influenced the work reported in this article.
References

al-Rodhan, N.R., Richelson, E., Gilbert, J.A., McCormick, D.J., Kanba, K.S., Pfenning, M.A., Nelson, A., Larson, E.W., Yaksh, T.L., 1991. Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem. Brain Res 557, 227-235.

Algera, M.H., Kamp, J., van der Schrier, R., van Velzen, M., Niesters, M., Aarts, L., Dahan, A., Olofsen, E., 2019. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. Br J Anaesth 122, e168-e179.

Angeby-Moller, K., Berge, O.G., Hamers, F.P., 2008. Using the CatWalk method to assess weight-bearing and pain behaviour in walking rats with ankle joint monoarthritis induced by carrageenan: effects of morphine and rofecoxib. J Neurosci Methods 174, 1-9.

Behbehani, M.M., Pert, A., 1984. A mechanism for the analgesic effect of neurotensin as revealed by behavioral and electrophysiological techniques. Brain Res 324, 35-42.

Bennett, G.J., Xie, Y.K., 1988. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man, Pain, pp. 87-107.

Benyamin, R., Trescot, A.M., Datta, S., Buenaventura, R., Adlaka, R., Sehgal, N., Glaser, S.E., Vallejo, R., 2008. Opioid Complications and Side Effects. Pain Physician 11, S105-S120.

Besserer-Offroy, E., Brouillette, R.L., Lavenus, S., Froehlich, U., Brumwell, A., Murza, A., Longpre, J.M., Marsault, E., Grandbois, M., Sarret, P., Leduc, R., 2017. The signaling signature of the neurotensin type 1 receptor with endogenous ligands. Eur J Pharmacol.

Besserer-Offroy, E., Sarret, P., 2019. Sending out Biased Signals: an Appropriate Proposition for Pain? Douleur et Analgésie 32, 108-110.
Besserer-Offroy, É., Tétreault, P., Brouillette, R.L., René, A., Murza, A., Fanelli, R., Kirby, K., Parent, A., Dubuc, I., Beaudet, N., Côté, J., Longpré, J.M., Martinez, J., Cavelier, F., Sarret, P., 2020. Data set describing the in vitro biological activity of JMV2009, a novel silylated neurotensin(8-13) analog. Data in Brief Under revision.

Bissette, G., Nemeroff, C.B., Loosen, P.T., Prange, A.J., Lipton, M.A., 1976. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin., Nature, pp. 607-609.

Bittermann, H., Einsiedel, J., Hubner, H., Gmeiner, P., 2004. Evaluation of lactam-bridged neurotensin analogues adjusting psi(Pro10) close to the experimentally derived bioactive conformation of NT(8-13). J Med Chem 47, 5587-5590.

Boules, M., Johnston, H., Tozy, J., Smith, K., Li, Z., Richelson, E., 2011. Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine. Behav Pharmacol 22, 573-581.

Boules, M., Liang, Y., Briody, S., Miura, T., Fauq, I., Oliveros, A., Wilson, M., Khaniyev, S., Williams, K., Li, Z., Qi, Y., Katovich, M., Richelson, E., 2010. NT79: A novel neurotensin analog with selective behavioral effects., Brain Res, pp. 35-46.

Boules, M., McMahon, B., Warrington, L., Stewart, J., Jackson, J., Fauq, A., McCormick, D., Richelson, E., 2001. Neurotensin analog selective for hypothermia over antinociception and exhibiting atypical neuroleptic-like properties., Brain Res, pp. 1-11.

Boules, M., Shaw, A., Liang, Y., Barbut, D., Richelson, E., 2009. NT69L, a novel analgesic, shows synergy with morphine., Brain Res, pp. 22-28.

Bowers, B.L., Crannage, A.J., 2017. The Evolving Role of Long-Term Pharmacotherapy for Opioid-Induced Constipation in Patients Being Treated for Noncancer Pain. J Pharm Pract, 897190017745395.
Bredeloux, P., Cavelier, F., Dubuc, I., Vivet, B., Costentin, J., Martinez, J., 2008. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier., J Med Chem, pp. 1610-1616.

Bredeloux, P., Costentin, J., Dubuc, I., 2006. Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice. Behav Brain Res 175, 399-407.

Bruneau, J., Ahamad, K., Goyer, M.E., Poulin, G., Selby, P., Fischer, B., Wild, T.C., Wood, E., Misuse, C.C.R.I.i.S., 2018. Management of opioid use disorders: a national clinical practice guideline. CMAJ 190, E247-E257.

Calam, J., Unwin, R., Peart, W.S., 1983. Neurotensin stimulates defaecation. Lancet 1, 737-738.

Cavelier, F., Marchand, D., Martinez, J., Sagan, S., 2004. Biological activity of silylated amino acid containing substance P analogues. J Pept Res 63, 290-296.

Cavelier, F., Marchand, D., Mbassi, P., Martinez, J., Marraud, M., 2006. Conformational studies of proline-, thiaproline- and dimethylsilaproline-containing diketopiperazines. J Pept Sci 12, 621-625.

Cavelier, F., Vivet, B., Martinez, J., Aubry, A., Didierjean, C., Vicherat, A., Marraud, M., 2002. Influence of silaprolone on peptide conformation and bioactivity., J. Am. Chem. Soc., pp. 2917-2923.

Chu, L.F., Clark, D.J., Angst, M.S., 2006. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 7, 43-48.
Cobos, E.J., Ghasemlou, N., Araldi, D., Segal, D., Duong, K., Woolf, C.J., 2012. Inflammation-induced decrease in voluntary wheel running in mice: A nonreflexive test for evaluating inflammatory pain and analgesia., Pain, pp. 876-884.

Collier, H.O.J., Dinneen, L.C., Johnson, C.A., Schneider, C., 1968. The Abdominal Constriction Response and Its Suppression by Analgesic Drugs in the Mouse. British Journal of Pharmacology and Chemotherapy 32, 295-310.

Coyle, D.T., Pratt, C.Y., Ocran-Appiah, J., Secora, A., Kornegay, C., Staffa, J., 2018. Opioid analgesic dose and the risk of misuse, overdose, and death: A narrative review. Pharmacoepidemiol Drug Saf 27, 464-472.

Dalkas, G.A., Marchand, D., Galleyrand, J.C., Martinez, J., Spyroulias, G.A., Cordopatis, P., Cavelier, F., 2010. Study of a lipophilic captopril analogue binding to angiotensin I converting enzyme. J Pept Sci 16, 91-97.

de Leon-Casasola, O.A., 2013. Opioids for chronic pain: new evidence, new strategies, safe prescribing., Am J Med, pp. S3-11.

Demeule, M., Beaudet, N., Regina, A., Besserer-Offroy, E., Murza, A., Tetreault, P., Belleville, K., Che, C., Larocque, A., Thiot, C., Beliveau, R., Longpre, J.M., Marsault, E., Leduc, R., Lachowicz, J.E., Gonias, S.L., Castaigne, J.P., Sarret, P., 2014. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. J Clin Invest 124, 1199-1213.

Deseure, K., Hans, G.H., 2017. Differential drug effects on spontaneous and evoked pain behavior in a model of trigeminal neuropathic pain. J Pain Res 10, 279-286.

Deuis, J.R., Dvorakova, L.S., Vetter, I., 2017. Methods Used to Evaluate Pain Behaviors in Rodents. Front Mol Neurosci 10, 284.
Devulder, J., Richarz, U., Nataraja, S.H., 2005. Impact of long-term use of opioids on quality of life in patients with chronic, non-malignant pain., Curr Med Res Opin, pp. 1555-1568.

Dobner, P.R., 2006. Neurotensin and pain modulation. Peptides 27, 2405-2414.

Dubuc, I., Costentin, J., Doulut, S., Rodriguez, M., Martinez, J., Kitabgi, P., 1992. JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse. Eur J Pharmacol 219, 327-329.

Dubuc, I., Pain, C., Suaudeau, C., Costentin, J., 1994. Tolerance to the hypothermic but not to the analgesic effect of [D-Trp11]neurotensin during the semichronic intracerebroventricular infusion of the peptide in rats. Peptides 15, 303-307.

Dubuisson, D., Dennis, S.G., 1977. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats., Pain, pp. 161-174.

Einsiedel, J., Held, C., Hervet, M., Plomer, M., Tschanmer, N., Hübner, H., Gmeiner, P., 2011. Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics., J Med Chem, pp. 2915-2923.

Eiselt, E., Cote, J., Longpre, J.M., Blais, V., Sarret, P., Gendron, L., 2019. The combination of opioid and neurotensin receptor agonists improves their analgesic/adverse effect ratio. Eur J Pharmacol 848, 80-87.

Fanelli, R., Berthomieu, D., Didierjean, C., Doudouh, A., Lebrun, A., Martinez, J., Cavelier, F., 2017. Hydrophobic alpha,alpha-Disubstituted Disilylated TESDpg Induces Incipient 310-Helix in Short Tripeptide Sequence. Org Lett 19, 2937-2940.

Fanelli, R., Besserer-Offroy, E., Rene, A., Cote, J., Tetreault, P., Collerette-Tremblay, J., Longpre, J.M., Leduc, R., Martinez, J., Sarret, P., Cavelier, F., 2015. Synthesis and Characterization in Vitro and in Vivo of (l)-(Trimethylsilyl)alanine Containing Neurotensin Analogues. J Med Chem 58, 7785-7795.
Fantegrossi, W.E., Ko, M.C., Woods, J.H., Richelson, E., 2005. Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Pharmacol Biochem Behav 80, 341-349.

Feifel, D., Goldenberg, J., Melendez, G., Shilling, P.D., 2010. The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacology 58, 195-198.

Feng, Y.-P., Wang, J., Dong, Y.-L., Wang, Y.-Y., Li, Y.-Q., 2014. The Roles of Neurotensin and its Analogues in Pain. Current Pharmaceutical Design 21, 840-848.

Fosgerau, K., Hoffmann, T., 2015. Peptide therapeutics: current status and future directions. Drug Discov Today 20, 122-128.

Gaumond, I., Spooner, M.-F., Marchand, S., 2007. Sex differences in opioid-mediated pain inhibitory mechanisms during the interphase in the formalin test., Neuroscience, pp. 366-374.

Gendron, L., Perron, A., Payet, M.D., Gallo-Payet, N., Sarret, P., Beaudet, A., 2004. Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2. Mol Pharmacol 66, 1421-1430.

Gomes, T., Mamdani, M.M., Paterson, J.M., Dhalla, I.A., Juurlink, D.N., 2014. Trends in high-dose opioid prescribing in Canada. Can Fam Physician 60, 826-832.

Guillemette, A., Dansereau, M.A., Beaudet, N., Richelson, E., Sarret, P., 2012. Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain., Eur J Pain, pp. 473-484.

Haley, T.J., McCormick, W.G., 1957. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12, 12-15.

Hapău, D., Rémond, E., Fanelli, R., Vivancos, M., René, A., Côté, J., Besserer-Offroy, É., Longpré, J.-M., Martinez, J., Zaharia, V., Sarret, P., Cavelier, F., 2016. Stereoselective Synthesis
of β-(5-Arylthiazolyl) α-Amino Acids and Use in Neurotensin Analogues. European Journal of Organic Chemistry 2016, 1017-1024.

Held, C., Hubner, H., Kling, R., Nagel, Y.A., Wennemers, H., Gmeiner, P., 2013. Impact of the proline residue on ligand binding of neurotensin receptor 2 (NTS2)-selective peptide-peptoid hybrids. ChemMedChem 8, 772-778.

Hellstrom, P.M., Rosell, S., 1981. Effects of neurotensin, substance P and methionine-enkephalin on colonic motility. Acta Physiol Scand 113, 147-154.

Heyl, D.L., Sefler, A.M., He, J.X., Sawyer, T.K., Wustrow, D.J., Akunne, H.C., Davis, M.D., Pugsley, T.A., Heffner, T.G., Corbin, A.E., et al., 1994. Structure-activity and conformational studies of a series of modified C-terminal hexapeptide neurotensin analogues. Int J Pept Protein Res 44, 233-238.

Hughes, F.M., Shaner, B.E., May, L.A., Zotian, L., Brower, J.O., Woods, R.J., Cash, M., Morrow, D., Massa, F., Mazella, J., Dix, T.A., 2010. Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic., J Med Chem, pp. 4623-4632.

Kaspar, A.A., Reichert, J.M., 2013. Future directions for peptide therapeutics development. Drug Discov Today 18, 807-817.

Kenakin, T., 2019. Biased Receptor Signaling in Drug Discovery. Pharmacol Rev 71, 267-315.

Kilkenny, C., Browne, W., Cuthill, I.C., Emerson, M., Altman, D.G., Group, N.C.R.R.G.W., 2010. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160, 1577-1579.

Kissin, I., 2010. The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth Analg 110, 780-789.
Kleckowska, P., Kosson, P., Ballet, S., Van Den Eynde, I., Tsuda, Y., Tourwé, D.,
Lipkowski, A.W., 2010. PK20, a new opioid-neurotensin hybrid peptide that exhibits central and
peripheral antinociceptive effects., Mol Pain, p. 86.

Kleckowska, P., Lipkowski, A.W., 2013. Neurotensin and neurotensin receptors:
characteristic, structure-activity relationship and pain modulation--a review. Eur J Pharmacol
716, 54-60.

Koster, R., Anderson, M., Debeer, E.J., 1959. Acetic Acid for Analgesic Screening. Fed
Proc 18, 412-412.

Krumm, B.E., Lee, S., Bhattacharya, S., Botos, I., White, C.F., Du, H., Vaidehi, N.,
Grisshammer, R., 2016. Structure and dynamics of a constitutively active neurotensin receptor.
Sci Rep 6, 38564.

Labbé-Jullié, C., Dubuc, I., Brouard, A., Doulut, S., Bourdel, E., Pelaprat, D., Mazella, J.,
Martinez, J., Rostène, W., Costentin, J., 1994. In vivo and in vitro structure-activity studies with
peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central
neurotensin receptor subtypes., J Pharmacol Exp Ther, pp. 328-336.

Lau, J.L., Dunn, M.K., 2018. Therapeutic peptides: Historical perspectives, current
development trends, and future directions. Bioorg Med Chem 26, 2700-2707.

Magafa, V., Matsoukas, M.T., Karageorgos, V., Dermitzaki, E., Exarchakou, R., Stylos, E.,
Pardalos, M., Margioris, A.N., Varvounis, G., Tzakos, A.G., Spyroulias, G.A., Liapakis, G.,
2019. Novel stable analogues of the neurotensin C-terminal hexapeptide containing unnatural
amino acids. Amino Acids 51, 1009-1022.

McGonigle, P., 2012. Peptide therapeutics for CNS indications., Biochem Pharmacol, pp.
559-566.
McNicol, E., Horowicz-Mehler, N., Fisk, R.A., Bennett, K., Gialeli-Goudas, M., Chew, P.W., Lau, J., Carr, D., 2003. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 4, 231-256.

Mogil, J.S., 2009. Animal models of pain: progress and challenges. Nat Rev Neurosci 10, 283-294.

Myers, R.M., Shearman, J.W., Kitching, M.O., Ramos-Montoya, A., Neal, D.E., Ley, S.V., 2009. Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors., ACS Chem Biol, pp. 503-525.

Nakazato-Imasato, E., Kurebayashi, Y., 2009. Pharmacological characteristics of the hind paw weight bearing difference induced by chronic constriction injury of the sciatic nerve in rats. Life Sci 84, 622-626.

Nemeroff, C.B., Osbahr, A.J., 3rd, Manberg, P.J., Ervin, G.N., Prange, A.J., Jr., 1979. Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine. Proc Natl Acad Sci U S A 76, 5368-5371.

Osbahr, A.J., 3rd, Nemeroff, C.B., Luttinger, D., Mason, G.A., Prange, A.J., Jr., 1981. Neurotensin-induced antinociception in mice: antagonism by thyrotropin-releasing hormone. J Pharmacol Exp Ther 217, 645-651.

Overington, J.P., Al-Lazikani, B., Hopkins, A.L., 2006. How many drug targets are there? Nat Rev Drug Discov 5, 993-996.

Pellissier, S., Eribon, O., Chabert, J., Gully, D., Roche, M., 1996. Peripheral neurotensin participates in the modulation of pre- and postprandial intestinal motility in rats. Neuropeptides 30, 412-419.
Perez de Vega, M.J., Ferrer-Montiel, A., Gonzalez-Muniz, R., 2018. Recent progress in non-opioid analgesic peptides. Arch Biochem Biophys 660, 36-52.

Remond, E., Martin, C., Martinez, J., Cavelier, F., 2016. Silicon-Containing Amino Acids: Synthetic Aspects, Conformational Studies, and Applications to Bioactive Peptides. Chem Rev 116, 11654-11684.

Remond, E., Martin, C., Martinez, J., Cavelier, F., 2017. Silaproline, a Silicon-Containing Proline Surrogate, in: Lubell, W.D. (Ed.), Peptidomimetics I. Springer International Publishing, pp. 27-50.

Rossi, G.C., Matulonis, J.E., Richelson, E., Barbut, D., Pasternak, G.W., 2010. Systemically and topically active antinociceptive neurotensin compounds, J Pharmacol Exp Ther, pp. 1075-1079.

Roussy, G., Dansereau, M.-A., Baudisson, S., Ezzoubaa, F., Belleville, K., Beaudet, N., Martinez, J., Richelson, E., Sarret, P., 2009. Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity., Mol Pain, p. 38.

Roussy, G., Dansereau, M.-A., Doré-Savard, L., Belleville, K., Beaudet, N., Richelson, E., Sarret, P., 2008. Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model., J Neurochem, pp. 1100-1114.

Sarret, P., Cavelier, F., 2018. Neurotensin and Its Receptors, Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier, pp. 1-17.

Sarret, P., Esdaile, M.J., Perron, A., Martinez, J., Stroh, T., Beaudet, A., 2005. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors., J Neurosci, pp. 8188-8196.

Sawynok, J., Liu, X.J., 2004. The Formalin Test: Characteristics and Usefulness of the Model, Reviews in Analgesia, pp. 145-163.
Sousbie, M., Vivancos, M., Brouillette, R.L., Besserer-Offroy, E., Longpre, J.M., Leduc, R., Sarret, P., Marsault, E., 2018. Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8-13). J Med Chem 61, 7103-7115.

Stone, L.S., Molliver, D.C., 2009. In search of analgesia: emerging roles of GPCRs in pain. Mol Interv 9, 234-251.

Tappe-Theodor, A., Kuner, R., 2014. Studying ongoing and spontaneous pain in rodents--challenges and opportunities. Eur J Neurosci 39, 1881-1890.

Tetreault, P., Beaudet, N., Perron, A., Belleville, K., Rene, A., Cavelier, F., Martinez, J., Stroh, T., Jacobi, A.M., Rose, S.D., Behlke, M.A., Sarret, P., 2013. Spinal NTS2 receptor activation reverses signs of neuropathic pain. FASEB J 27, 3741-3752.

Thor, K., Rosell, S., 1986. Neurotensin increases colonic motility. Gastroenterology 90, 27-31.

Tokumura, T., Tanaka, T., Sasaki, A., Tsuchiya, Y., Abe, K., Machida, R., 1990. Stability of a novel hexapeptide, (Me)Arg-Lys-Pro-Trp-tert-Leu-Leu-OEt, with neurotensin activity, in aqueous solution and in the solid state. Chem Pharm Bull (Tokyo) 38, 3094-3098.

Tomita, R., Igarashi, S., Fujisaki, S., Tanjoh, K., 2007. The effects of neurotensin in the colon of patients with slow transit constipation. Hepatogastroenterology 54, 1662-1666.

Tyler, B.M., Cusack, B., Douglas, C.L., Souder, T., Richelson, E., 1998. Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Res 792, 246-252.

Tyler-McMahon, B.M., Stewart, J.A., Farinas, F., McCormick, D.J., Richelson, E., 2000. Highly potent neurotensin analog that causes hypothermia and antinociception. Eur J Pharmacol 390, 107-111.
Tétreault, P., Dansereau, M.-A., Doré-Savard, L., Beaudet, N., Sarret, P., 2011. Weight bearing evaluation in inflammatory, neuropathic and cancer chronic pain in freely moving rats., Physiol. Behav., pp. 495-502.

Vivet, B., Cavelier, F., Martinez, J., 2000. Synthesis of silaproline, a new proline surrogate. European Journal of Organic Chemistry 2000, 807-811.

White, J.F., Noinaj, N., Shibata, Y., Love, J., Kloss, B., Xu, F., Gvozdenovic-Jeremic, J., Shah, P., Shiloach, J., Tate, C.G., Grisshammer, R., 2012. Structure of the agonist-bound neurotensin receptor. Nature 490, 508-513.

Wustrow, D.J., Davis, M.D., Akunne, H.C., Corbin, A.E., Wiley, J.N., Wise, L.D., Heffner, T.G., 1995. Reduced amide bond neurotensin 8-13 mimetics with potent in vivo activity. Bioorg. Med Chem Lett 5, 997-1002.

Yaksh, T.L., Hunt, M.A., Dos Santos, G.G., 2018. Development of New Analgesics: An Answer to Opioid Epidemic. Trends Pharmacol Sci 39, 1000-1002.

Yamauchi, R., Sonoda, S., Jinsmaa, Y., Yoshikawa, M., 2003. Antinociception induced by beta-lactotensin, a neurotensin agonist peptide derived from beta-lactoglobulin, is mediated by NT2 and D1 receptors. Life Sci 73, 1917-1923.

Zogovic, B., Pilowsky, P.M., 2012. Intrathecal neurotensin is hypotensive, sympathoinhibitory and enhances the baroreflex in anaesthetized rat. Br J Pharmacol 166, 378-389.
Figure legends

Fig. 1. Antinociceptive response to i.t. injection of JMV2009 in the tail-flick test. (A) Dose- and time-dependent antinociceptive effect of JMV2009 (3, 30, and 90 µg/kg) on tail-flick latencies in rats. Baseline latencies were taken three times before acute i.t. injection of JMV2009. Latencies were determined every 10 min for up to 60 min and a final measure was taken at 90 min following drug administration. ** P < 0.01 (JMV2009, 3 µg/kg vs. Saline); ††† P < 0.01 (JMV2009, 30 µg/kg vs. Saline); ⌧ P < 0.05, and †† P < 0.001 (JMV2009, 90 µg/kg vs. Saline) in a two-way ANOVA (F(7, 393) = 25.40) followed by a Dunnett’s post hoc test. (B) Percentage of maximum possible effect (MPE) ± S.E.M. determined at the time of peak anti-nociceptive response (40 min) for each dose (3, 30, and 90 µg/kg). * P < 0.05 and *** P < 0.001 (JMV2009 vs. Saline) in a Kruskal-Wallis test (χ²(3) = 19.48, P = 0.0002) followed by a Dunn’s correction for multiple comparisons. Each data point represents the mean ± S.E.M. n = 8 rats per group.
Fig. 2. Effects of central administration of JMV2009 on tonic and visceral pain. (A) Reduction of the nocifensive behaviors after i.t. injection of JMV2009 (3 and 30 µg/kg) in the formalin-induced tonic pain model. * $P < 0.05$ (JMV2009, 3 µg/kg vs. Saline) and ### $P < 0.01$ (JMV2009, 30 µg/kg vs. Saline) in a two-way ANOVA ($F(2, 455) = 168.7$) followed by a Dunnett’s post hoc test. (B) The cumulative nociceptive response, expressed as mean area under the curve (AUC) ± S.E.M., is measured during the inflammatory phase of the formalin test (21 – 60 min). *** $P < 0.001$ (JMV2009 vs. Saline) in a Kruskal-Wallis test ($\chi^2(2) = 17.82, P = 0.0001$) followed by a Dunn’s correction for multiple comparisons. Each symbol represents the mean ± S.E.M. of determinations made in 6 rats. (C) Dose-dependent antinociceptive effects of JMV2009 (0.4, 4, 12 and 40 µg/kg, i.c.v.) in the acetic acid-induced writhing model in mice. Writhes were counted over a 5-min period after i.p. injection of 0.5% acetic acid. ** $P < 0.01$ and *** $P < 0.001$ (vs. Saline), ## $P < 0.01$ ( JMV2009 40 vs. JMV2009, 0.4 µg/kg) in a Kruskal-Wallis test ($\chi^2(4) = 31.06, P < 0.0001$) followed by a Dunn’s correction for multiple comparisons. The number of indicated writhes is the mean ± S.E.M. from groups of 6 mice. (D) Dose-response curve of JMV2009-induced antinociception in the acetic acid in the writhing model in mice. JMV2009 displayed an ED$_{50}$ of 2.33 ± 0.6 µg/kg, as determined by non-linear regression fit in GraphPad Prism ($R^2 = 0.61$).
Fig. 3. Effects of JMV2009 on mechanical allodynia induced by the chronic constriction injury (CCI) of the sciatic nerve in rats. (A) Paw withdrawal thresholds were assessed with an automated von Frey hair during the 4-week period after CCI surgery. Baseline (BL) withdrawal thresholds were determined for all CCI- and sham-operated rats prior to surgery. In neuropathic rats, acute i.t. injection of JMV2009 (3, 30, and 90 µg/kg) at day 3, 7, 14, 21, and 28 post-surgery effectively reduces the mechanical hypersensitivity. ** $P < 0.01$, *** $P < 0.001$ (JMV2009, 3 µg/kg vs. CCI); ### $P < 0.001$ (JMV2009, 30 µg/kg vs. CCI); ††† $P < 0.001$ (JMV2009, 90 µg/kg vs. CCI) in a two-way ANOVA ($F(4, 182) = 236.8$) followed by a Dunnett’s post hoc test. (B) Percentage of anti-allodynia calculated over the 3-28 day period. All tested doses of JMV2009 were effective to attenuate the development of mechanical allodynia. *** $P < 0.001$ (JMV2009 vs. Saline) in a Kruskal-Wallis test ($\chi^2(3)= 26.59, P < 0.0001$) followed by a Dunn’s correction for multiple comparisons. Vertical bars represent S.E.M. (n = 6 per group).
Fig. 4. Effects of JMV2009 on neuropathy-induced weight-bearing deficits and decrease in time-of-use of the injured limb. (A) Weight bearing impairment was measured using the dynamic weight bearing (DWB) after acute i.t. injection of JMV2009 (30 µg/kg) at day 3, 7, 14, 21, and 28 post-surgery. Baseline values (BL) were assessed before CCI surgery. * \( P < 0.05 \) and ** \( P < 0.01 \) (JMV2009, 30 µg/kg vs. CCI) in a two-way ANOVA (F(2, 30) = 61.79) followed by a Dunnett’s post hoc test. (B) Treatment effectiveness was determined by measuring the percentage of weight recovery over the 3-28 day period, with 100% corresponding to full recovery in the weight borne on the injured limb. *** \( P < 0.001 \) in a two-tailed Mann-Whitney test. (C) Percentage of time spent on the injured limb was determined using the DWB device over the 28-day period following CCI surgery. * \( P < 0.05 \) (JMV2009, 30 µg/kg vs. CCI) in a two-way ANOVA (F(2, 30) = 19.19) followed by a Dunnett’s post hoc test. (D) Determination of the percentage of functional rehabilitation was examined over the 28-day period after acute administration of JMV2009. 100% rehabilitation corresponds to a full recovery in the use of the injured limb. * \( P < 0.05 \) in a two-tailed Mann-Whitney test. Each symbol represents the mean ± S.E.M. of determinations made in 6 rats.
Fig. 5. Effects of JMV2009 on opioid and neurotensin-related adverse effects. (A)
Gastrointestinal tract motility assessed by measuring the progression of a charcoal meal in the intestine. Results are expressed as percentage of distance travelled by the active charcoal 30 min after the s.c. injection of either saline (1 ml/kg), Morphine sulfate, neurotensin (NT), or JMV2009 (10 mg/kg). *** $P < 0.001$ (vs. Saline) in a Kruskal-Wallis test ($\chi^2(3) = 18.95, P = 0.0003$) followed by a Dunn’s correction for multiple comparisons. Each data point represents the mean ± S.E.M. n = 6 rats per group. (B) Effect of chronic treatment with JMV2009 (30 µg/kg/day, i.t. for five consecutive days) or Saline (25 µl/day, i.t. for five consecutive days) on the antinociceptive action of JMV2009 (90 µg/kg). The analgesic effect was assessed using the tail-flick thermal test. No statistical differences were found between the anti-nociceptive responses of Saline- or JMV2009-pretreated animals (two-way ANOVA (F(1, 117) = 1.352) followed by a Dunnett’s post hoc test). Each symbol represents the mean ± S.E.M. of determinations made in 8 rats. (C) Hypothermia induced by acute i.t. injection of saline, JMV2009 (3, 30, and 90 µg/kg) and the NTS$_1$-selective compound PD149163 (30 µg/kg). Baseline body temperature (BL) assessment was performed before i.t. injection. As opposed to PD149163, JMV2009 did not induce changes in body temperature ($\Delta$ Body Temperature). *** $P < 0.001$ (PD149163, 30 µg/kg vs. Saline) in a two-way ANOVA (F(4, 231) = 22.19) followed by a Dunnett’s post hoc test. Error bars represent mean ± S.E.M. of determinations made in 8 rats. (D) Maximal effect of JMV2009 or NT on mean arterial blood pressure recorded on anesthetized rats after i.v. injection at a dose of 0.1 mg/kg. Each data point represents the mean ± S.E.M. n = 6 rats per group.
Figures

A

Latency (s)

Time (min)

Saline

JMV2009 (30)

JMV2009 (3)

JMV2009 (90)

B

MPE (%)

JMV2009 dose (µg/kg)

Saline

3

30

90

Fig. 1
Fig. 2
Fig. 3

A

Withdrawal threshold (g)

Time (days)

BL 3 7 14 21 28

Sham

JMV2009 (90)

JMV2009 (30)

JMV2009 (3)

CCI

B

Anti-allodynia (%)

JMV2009 dose (µg/kg)

CCI 3 30 90

0 20 40 60 80 100

***

***  ***

A

B
Fig. 4
Fig. 5